LivingGLP1
Study S001097

Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT00359762
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
NONE
Status
COMPLETED
Enrollment
1029
Start
2006-09
Primary completion
2011-03
Lead sponsor
AstraZeneca
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:exenatide; DRUG:glimepiride
Results posted
TRUE

Registered primary outcomes

  • Number of Patients With Treatment Failure [Baseline to end of Period II (up to 4.5 years)]
  • Time to Treatment Failure [Baseline to end of Period II (up to 4.5 years)]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0016082Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R, Cardiovascular diabetology
2015Randomized trialPMID 26338040DOIcites ClinicalTrials.gov:NCT00359762; registry reference DERIVED:26338040
R0025966Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Schernthaner G, Diabetes, obesity & metabolism
2015Randomized trialPMID 25846577DOIcites ClinicalTrials.gov:NCT00359762; registry reference DERIVED:25846577
R0026887Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
Gallwitz B, Lancet (London, England)
2012Randomized trialPMID 22683137DOIcites ClinicalTrials.gov:NCT00359762; registry reference DERIVED:22683137